PHARMIG - Verband der pharmazeutischen Industrie Österreichs

epsilon 3

Prinz-Eugen-Straße 18/20
1040 Wien
Tel.: +43 01406355515
E-Mail: office@epsilon3.at
Webseite: www.epsilon-3.com

epsilon 3 has developed a novel drug repurposing technology for adding value to approved drugs as well as to compounds in preclinical and clinical development. Our methodology for repositioning/repurposing of compounds or drugs for diseases other than those for which the assets were originally intended is based on large data integration and subsequent analytics embedded in our novel epsilon 3 computational workflow, integrated with a standardized experimental confirmation module.

Internationale Firmenkenndaten

The epsilon 3 team consists of specialists in the fields of bioinformatics and computational biology, molecular biology including omics technologies, medicine and pharmaceutical drug development including marketing aspects.

Forschungsschwerpunkte

  • Repositioning
  • Seltene Erkrankungen
  • Immunologische und entzündliche Krankheiten
  • Neurologie und Schmerz
  • Onkologie

Therapiegebiete

  • Erkrankungen des zentralen Nervensystems
  • Nierentransplantation
  • Seltene Erkrankungen
  • Onkologie
Die Daten wurden via Pharmig-Umfrage 2017 erhoben.